InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the Company presented the pre-clinical data of its pan-TRK small molecule inhibitor ICP-723 at the 113th annual meeting of the American Association for Cancer Research (AACR) in 2022.

This report was displayed in a poster entitled “ICP-723 Is a Potent Pan-TRK Inhibitor with Robust Anti-tumor Activities against Wild-type and Acquired Drug-resistant Mutations of NTRK Fusions”. Abstract number: 6187.

The study showed that ICP-723 effectively inhibits kinase activities of TRKA, TRKB, TRKC with IC₅₀ values < 1 nM.

ICP-723 demonstrates robust in vitro efficacy in all wild-type TRK-driven tumors. It also overcomes solvent front mutations (e.g., TRKA G595R, TRKC G623R/E) often developed following first generation TRK inhibitor treatment.

In vivo efficacy studies further demonstrate its robust anti-tumor efficacies in xenograft models. Treatment with 1 mg/kg of ICP-723 results in 89.5% TGI of KM12 tumors.

The pharmacokinetic parameters of ICP-723 are overall favorable, with high oral bioavailability.

Dr. Jasmine Cui, Co-Founder, Chairwoman and CEO of InnoCare, said, “As a novel second generation pan-TRK inhibitor, ICP-723 has broad-spectrum anti-tumor activities against wild-type and various acquired drug-res istant mutations of NTRK

gene fusions. It is expected to bring new options for the treatment of NTRK fusion-positive cancer. InnoCare is now conducting clinical trial of ICP-723 in China and U.S., and please stay tuned on the latest clinical data in the upcoming international conference.”

The AACR Annual Meeting is held online and offline in New Orleans, U.S. from April 8th to 13th, 2022, which is one of the largest cancer research conferences in the world, attracting professionals all over the world every year.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, New Jersey and Boston.